Vanguard's 5%+ stake is routine for a large passive manager and does not signal activist intent. Monitor for any future 13D conversion or additional insider buying, but this filing alone is not a catalyst.
Price Chart
Executive Summary
Vanguard Capital Management disclosed a 5.04% passive stake in Immunome Inc. as of September 30, 2026, holding 5,725,578 shares. This is a new SC 13G filing (not an amendment), indicating Vanguard crossed the 5% threshold for the first time. The filing certifies passive intent with no plan to influence control.
Key Financial Metrics
Key Facts
- Vanguard Capital Management reported beneficial ownership of 5,725,578 shares of Immunome Inc. common stock.
- The stake represents 5.04% of shares outstanding as of September 30, 2026.
- This is an initial SC 13G filing, not an amendment, meaning Vanguard newly crossed the 5% threshold.
- Vanguard certifies the shares were acquired in the ordinary course of business and not with the purpose of changing or influencing control.
- Vanguard is a large passive index fund manager; the stake is consistent with its typical passive investment approach.
Financial Impact
5.04% stake valued at approximately $111 million based on $2.2B market cap.
Risk Factors
- No material risk identified from this passive disclosure.
- The filing does not provide insight into Vanguard's future trading plans.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G Filing (Primary) | 0002100119-26-001633 |
| Document: 0002100119-26-001633-index.html | 0002100119-26-001633 |
| Document: 0002100119-26-001633.txt | 0002100119-26-001633 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 30, 2026 2d ago | SC 13G | $17.96 | awaiting T+60 | awaiting T+60 | $18.21 (+1.39%) |
Oct 16, 2026 16d ago | ANALYST-UPGRADE | $16.47 | awaiting T+60 | awaiting T+60 | $18.21 (+10.56%) |
Oct 5, 2026 27d ago | 8-K | $21.17 | awaiting T+60 | awaiting T+60 | $18.21 (−13.98%) |
Oct 1, 2026 4w ago | ANALYST-UPGRADE | $20.89 | awaiting T+60 | awaiting T+60 | $18.21 (+12.83%) |
Sep 21, 2026 5w ago | ANALYST-UPGRADE | $25.07 | awaiting T+60 | awaiting T+60 | $18.21 (−27.36%) |
Aug 12, 2026 11w ago | Insider Cluster | $26.42 | awaiting T+60 | awaiting T+60 | $18.21 (−31.07%) |
Aug 10, 2026 11w ago | Insider Cluster | $26.25 | awaiting T+60 | awaiting T+60 | $18.21 (−30.63%) |
Jul 9, 2026 16w ago | Insider Cluster | $23.35 $21.17 | ▼ −9.34% | ▼ −11.97% | $18.21 (−22.01%) |
Jul 7, 2026 16w ago | Insider Cluster | $24.01 $20.89 | ▼ −12.99% | ▼ −15.49% | $18.21 (−24.16%) |
Jul 7, 2026 16w ago | Insider Cluster | $24.01 $20.89 | ▼ −12.99% | ▼ −15.49% | $18.21 (−24.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers